StockNow
CalendarLog in
Global Markets

Novo’s (NOVOB DC) once-weekly Sogroya (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

StockNow breaking-news AI analysis

Novo's Sogroya received a positive CHMP opinion in Europe, potentially making it the first growth hormone approved in the EU for children with idiopathic short stature.

News detail

If approved, Sogroya (somapacitan) would be the first and only growth hormone treatment approved for idiopathic short stature in the EU, providing a much-needed treatment option for children and their families affected by this condition.

1 stocks
NVONovo-Nordisk A/S$43.37Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

UKMTO has received a report of an incident in the Strait of Hormuz; The CSO of a vessel has reported a tanker being hit by an unknown projectile causing a fire, which was extinguished

Commodities

Saudis reportedly tells Europe oil refiners that they will get no crude next month

Politics

ECB President Lagarde says rates do not move in lockstep with energy prices, and that other factors play a role